Evidence map›Paper›PMID 36469564›Full record

ArticleRNA biology2022

MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.

Felix Prinz, Katharina Jonas, Amar Balihodzic, Christiane Klec, Andreas Reicher, Dominik Andreas Barth, Jakob Riedl, Armin Gerger, Tobias Kiesslich, Christian Mayr and 3 more

Open access · goldAbstract read
In one paragraph

Article in RNA biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. MicroRNA-200c in Cancer Generation, Invasion, and Metastasis.International journal of molecular sciences · 2025
    Review
  4. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Felix PrinzDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Katharina JonasDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Amar BalihodzicDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Christiane KlecDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Andreas ReicherDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Dominik Andreas BarthDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Jakob RiedlDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Armin GergerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Tobias KiesslichCenter for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology Salzburg, Paracelsus Medical University, Salzburg, Austria.
Christian MayrCenter for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology Salzburg, Paracelsus Medical University, Salzburg, Austria.
Beate RinnerDivision of Biomedical Research, Medical University of Graz, Graz, Austria.
Julia KarglDivision of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria.
Martin PichlerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Medical University of Graz · ATParacelsus Medical University · AT

Funding

Austrian Science Fund FWF W 1226
6 · The paper itself

Abstract

The microRNA-200 family has wide-ranging regulatory functions in cancer development and progression. Above all, it is strongly associated with the epithelial-to-mesenchymal transition (EMT), a process during which cells change their epithelial to a mesenchymal phenotype and acquire invasive characteristics. More recently, miR-200 family members have also been reported to impact the immune evasion of cancer cells by regulating the expression of immunoinhibitory immune checkpoints (ICs) like PD-L1. Therefore, we aimed to comprehensively characterize this miR-200 family as a regulatory interface between EMT and immune evasion mechanisms in biliary tract cancer. Initial correlation analyses and transient overexpression experiments using miRNA mimics suggested miR-200c-3p as a putative regulator of ICs including PD-L1, LGALS9, and IDO1. However, these effects could not be confirmed in stable miR-200c-3p overexpression cell lines, nor in cells transiently transfected with miR-200c-3p mimic from an independent manufacturer. By shifting our efforts towards dissecting the mechanisms leading to these disparate effects, we observed that the initially used miR-200c-3p mimic triggered a double-stranded (ds)RNA-dependent antiviral response. Besides upregulating the ICs, this had substantial cellular consequences including an induction of interferon type I and type III expression, increased levels of intracellular dsRNA sensors, and a significantly altered cellular growth and apoptotic activity.Our study highlights the capability of miRNA mimics to non-specifically induce a dsRNA-mediated antiviral interferon response. Consequently, phenotypic alterations crucially distort physiological miRNA functions and might result in a major misinterpretation of previous and future miRNA studies, especially in the context of IC regulation.

Indexed as

MicroRNAsAntiviral AgentsB7-H1 AntigenCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticInterferonsAntiviral AgentsB7-H1 AntigenInterferonsMicroRNAsantiviral responsedsRNA sensingimmune checkpointsinterferonsMicroRNA mimicsmiR-200c-3pnon-specific effects

Identifiers

PMID36469564
PMCPMC9728468
OpenAlexW4311138502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.